1. Search Result
Search Result
Results for "

cluster of differentiation 47 (CD47)

" in MedChemExpress (MCE) Product Catalog:

501

Inhibitors & Agonists

3

Screening Libraries

10

Fluorescent Dye

46

Biochemical Assay Reagents

38

Peptides

47

Inhibitory Antibodies

59

Natural
Products

222

Recombinant Proteins

29

Isotope-Labeled Compounds

265

Antibodies

4

Click Chemistry

14

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990131
    Anti-Mouse CD47/IAP Antibody (MIAP301)
    1 Publications Verification

    CD47 Infection Inflammation/Immunology Cancer
    Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for research on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .
    Anti-Mouse CD47/IAP Antibody (MIAP301)
  • HY-P990132

    CD47 Inflammation/Immunology Cancer
    Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for research on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .
    Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410)
  • HY-P99172

    CD47 Interleukin Related Cancer
    CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
    CC-90002
  • HY-P990858

    CD47 Cancer
    Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47 Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47 Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47 Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47 Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma .
    Anti-CD47 Antibody (B6.H12)
  • HY-P99533

    SRF-231; SRF231

    CD47 Interleukin Related Cancer
    Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
    Urabrelimab
  • HY-RS02250

    Small Interfering RNA (siRNA) CD47 Others

    CD47 Human Pre-designed siRNA Set A contains three designed siRNAs for CD47 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD47 Human Pre-designed siRNA Set A
    CD47 Human Pre-designed siRNA Set A
  • HY-RS16548

    Small Interfering RNA (siRNA) Others

    Cd47 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd47 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd47 Mouse Pre-designed siRNA Set A
    Cd47 Mouse Pre-designed siRNA Set A
  • HY-RS22981

    Small Interfering RNA (siRNA) Others

    Cd47 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cd47 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd47 Rat Pre-designed siRNA Set A
    Cd47 Rat Pre-designed siRNA Set A
  • HY-P991085

    PD-1/PD-L1 Cancer
    HX009 is a bispecific antibody targeting PD1 and CD47, but with weakened CD47 binding. HX009 blocks the functional of PD1/CD47. HX009 can be used for the study of non-Hodgkin’s lymphoma (NHL) .
    HX009
  • HY-P991518

    PD-1/PD-L1 CD47 Cancer
    IBI-322 is a bispecific antibody targeting PD-L1 and CD47. IBI-322 attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
    IBI-322
  • HY-143224

    CD47 Cancer
    NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis .
    NCGC00138783
  • HY-143224B

    CD47 Cancer
    NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis .
    NCGC00138783 TFA
  • HY-115983

    CD47 Apoptosis Cancer
    DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity .
    DMUP
  • HY-143224A

    CD47 Cancer
    NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis .
    NCGC00138783 free base
  • HY-P990707

    TTI-622; PF-07901801

    CD47 Inflammation/Immunology
    Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47 .
    Maplirpacept
  • HY-P991062

    Gensci-059

    CD47 Cancer
    Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Gentulizumab
  • HY-P10813

    CD47 Inflammation/Immunology Cancer
    ZLIRTLHEWY is a potent peptide CD47/SIRPα interaction inhibitor. ZLIRTLHEWY is promising for research of cancers .
    ZLIRTLHEWY
  • HY-P99950

    ALX148

    CD47 Cancer
    Evorpacept is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region .
    Evorpacept
  • HY-P10420

    CD47 Interleukin Related Cancer
    RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape .
    RS17
  • HY-P99777

    TTI-621

    CD47 Cancer
    Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
    Ontorpacept
  • HY-P990723

    CD47 Cancer
    Timdarpacept (DNL310) is a recombinant SIRPa-Fc fusion protein that can activate macrophages to enhance anti-tumor activity by blocking CD47-SIRPa .
    Timdarpacept
  • HY-143225

    CD47 Others
    NCGC00538431 is a potent modulator of SIRPα-CD47 .
    NCGC00538431
  • HY-P3968

    CD47 Others
    Thrombospondin-1 (1016-1021) (human, bovine, mouse), a Thrombospondin-1-derived peptide, is a truncated peptide devoid of CD47-binding activity .
    Thrombospondin-1 (1016-1021) (human, bovine, mouse)
  • HY-P991016

    PT-217

    CD47 Inflammation/Immunology
    HY-P991016 is an CD47/DLL3-targeting H-γ1_L-κ type bispecific antibody .
    Peluntamig
  • HY-P991560

    CD47 Cancer
    TQB-2928 is a monoclonal antibody against CD47, which can be used in the study of cancer.
    TQB-2928
  • HY-P990694

    TG-1801

    CD19 CD47 Inflammation/Immunology
    Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Zeripatamig
  • HY-P99029
    Magrolimab
    2 Publications Verification

    Hu5F9-G4

    CD47 Cancer
    Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
    Magrolimab
  • HY-P991027

    CD47 Inflammation/Immunology
    HY-P991027 is an CD47/CLDN18-targeting (H-γ1_L-κ)_(H-γ1_L-κ) type bispecific antibody .
    Spevatamig
  • HY-P991561

    CD47 Cancer
    AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
    AO-176
  • HY-P991004

    CD47 Inflammation/Immunology
    HY-P991004 is an CD274/CD47-targeting (VH-G1CH1-h)-H-γ1_L-κ-L-κ type bispecific antibody .
    Itanistomig
  • HY-P990954

    CD47 Inflammation/Immunology
    HY-P990954 is an MS4A1/CD47-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
    Amulirafusp alfa
  • HY-P990899

    CD47 Inflammation/Immunology
    HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
    Amostomig
  • HY-P991023

    CD47 Inflammation/Immunology
    HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Safimestomig
  • HY-P99026

    TJ011133; TJC4

    CD47 Cancer
    Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .
    Lemzoparlimab
  • HY-P0144

    CD47 Apoptosis Inflammation/Immunology
    Thrombospondin-1 (1016-1023) (human, bovine, mouse), is the C-terminal end of the native sequence of Thrombospondin-1 (TSP-1), is a CD47 agonist peptide .
    Thrombospondin-1 (1016-1023) (human, bovine, mouse)
  • HY-P99706

    AK 117

    CD47 Interleukin Related Cancer
    Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
    Ligufalimab
  • HY-151132

    IsoQC-IN-1

    CD47 Cancer
    Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC50 values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of CD47/SIRPα through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages .
    Glutaminyl cyclases-IN-1
  • HY-P990962

    EGFR Inflammation/Immunology
    HY-P990962 is an EGFR/CD47-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
    Vislarafusp alfa
  • HY-P10388

    CD47 TGF-β Receptor Cancer
    TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2 (vascular endothelial growth factor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment .
    TAX2 peptide
  • HY-P990289

    Transmembrane Glycoprotein Infection
    Anti-Mouse CD172a Antibody (P84) is a rat-derived anti-mouse CD172a IgG1 κ type antibody inhibitor. Anti-Mouse CD172a Antibody (P84) blocks CD47-SIRPα interaction and thereby augments cell phagocytosis. Anti-Mouse CD172a Antibody (P84) can be used for the researches of infection and immunology, such as salmonella typhimurium infection .
    Anti-Mouse CD172a Antibody (P84)
  • HY-P99175

    CD47 Cancer
    KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
    KWAR 23
  • HY-120284

    Microtubule/Tubulin Cancer
    CCCI-01 is a centrosome clustering inhibitor. CCCI-01 has selective effects on cancer. CCCI-01 can be used for the research of non-cross-resistant anti-cancer agents with blocking centrosome clustering .
    CCCI-01
  • HY-P3970

    TGF-β Receptor Inflammation/Immunology
    KRFK, a peptide derived from TSP-1, can activate TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach .
    KRFK
  • HY-P3970A
    KRFK TFA
    3 Publications Verification

    TGF-β Receptor Inflammation/Immunology
    KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach .
    KRFK TFA
  • HY-116681

    Insecticide Infection
    Aflavarin is produced from cluster 39 expressed mainly in sclerotia. Aflavarin exhibits anti-insectan activity .
    Aflavarin
  • HY-P991057

    CD47 Cancer
    STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    STI-6643
  • HY-136780

    Amyloid-β Apoptosis CD47 Huntingtin Neurological Disease Cancer
    SEN177 is an orally effect glutamine cyclase (QC) inhibitor. The Ki of SEN177 for human glutamine cyclase (hQC) is 20 nM, and the IC50 is 13 nM. SEN177 interferes with the interaction between CD47 and SIRRPα, and has anti-tumor activity. SEN177 reduces aggregation and apoptosis caused by HTT mutation in Huntington model, and can be used in the study of neurodegenerative diseases .
    SEN177
  • HY-P990033

    CC-95251; BMS-986351

    CD47 Cancer
    Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
    Anzurstobart
  • HY-16438
    RRx-001
    15+ Cited Publications

    Nibrozetone

    CD47 Apoptosis Parasite Infection Inflammation/Immunology Cancer
    RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity . RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α . RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity .
    RRx-001
  • HY-P99021
    Galcanezumab
    1 Publications Verification

    LY 2951742

    CGRP Receptor Neurological Disease
    Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
    Galcanezumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: